FindTrial
Sign In

Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71212234
Enrollment
Unknown
Registered
2001-07-01
Start date
1989-01-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (Hodgkin's) Cancer Lymphoma (Hodgkin's)

Interventions

Patients are randomised to one of two chemotherapy regimens: 1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hodgkin's lymphoma stage IIB, III or IV 2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV) 3. Local hisopathological review of diagnosis 4. No medical contraindications to treatment protocols

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026